A PYMNTS Company

US: Thermo Fisher to buy Brammer Bio for US$1.7B

By  |  March 25, 2019

Thermo Fisher Scientific, the world’s largest maker of scientific instruments, announced on Sunday, March 24, it has agreed to buy Brammer Bio in a roughly US$1.7 billion cash deal.

Closely held Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drugmaking services.

Gene therapies aim to replace defective genes with healthy ones, and researchers consider them to be a promising treatment option for intractable inherited diseases. Nearly 300 gene therapies are under development, aiming to treat more than 100 diseases, according to a recent report from a drug-industry trade group.

Full Content: Wall Street Journal

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.